Conditional lethality of the diprotic weak bases chloroquine and quinacrine against Cryptococcus neoformans

Journal of Infectious Diseases

Volumn 182, Issue 1, 2000, Pages 283-289

  Harrison, Thomas S ^a   Griffin, George E ^a   Levitz, Stuart M ^b  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; MEPACRINE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; GENE DISRUPTION; GROWTH INHIBITION; INHIBITION KINETICS; NONHUMAN; PRIORITY JOURNAL; STRAIN DIFFERENCE;

ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; CELL DIVISION; CHLOROQUINE; CRYPTOCOCCUS NEOFORMANS; DRUG COMBINATIONS; ENZYME INHIBITORS; MACROLIDES; MICROBIAL SENSITIVITY TESTS; QUINACRINE;

EID: 0033943341     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315649     Document Type: Article

References (38)

1. 1. Wenzel RP, Pfaller MA. Candida species: emerging hospital bloodstream pathogens. Infect Control Hosp Epidemiol 1991; 12:523-4.
2. 2. Groll AH, Shah PM, Mentzel C, et al. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 1996; 33:23-32.
3. 3. Casadevall A, Perfect JR. Cryptococcus neoformans. Washington, DC: American Society for Microbiology Press, 1998.
4. 4. White TC, Marr KA, Bowden RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 1998; 11:382-402.
5. 5. O'Neill PM, Bray PG, Hawley SR, Ward SA, Kevin Park B. 4-aminoquinolines - past, present, and future: a chemical perspective. Pharmacol Ther 1998; 77:29-58.
6. 6. Finkelstein DB, Strausberg S. Metabolism of alpha factor by a mating type cells of Saccharomyces cerevisiae. J Biol Chem 1979; 254:796-803.
7. 7. Ruetz S, Delling U, Brault M, Schurr E, Gros P. The pmfdr1 gene of Plasmodium falciparum confers cellular resistance to antimalarial drugs in yeast cells. Proc Natl Acad Sci USA 1996; 93:9942-7.
8. 8. Delling U, Raymond M, Schurr E. Identification of Saccharomyces cerevisiae genes conferring resistance to quinoline ring containing antimalarial drugs. Antimicrob Agents Chemother 1998; 42:1034-41.
9. 9. Weisman LS, Bacallao R, Wickner W. Multiple methods of visualizing the yeast vacuole permit evaluation of its morphology and inheritance during the cell cycle. J Cell Biol 1987; 105:1539-47.
10. 10. Levitz SM, Harrison TS, Tabuni A, Liu X. Chloroquine induces human mononuclear phagocytes to inhibit and kill Cryptococcus neoformans by a mechanism independent of iron deprivation. J Clin Invest 1997; 100: 1640-6.
11. 11. Krogstad DJ, Schlesinger PH. Acid-vesicle function, intracellular pathogens, and the action of chloroquine against Plasmodium falciparum. N Engl J Med 1987; 317:542-9.
12. 12. Levitz SM, Nong S, Seetoo K, Harrison TS, Speizer R, Simons E. Cryptococcus neoformans resides in an acidic phagolysosome of human macrophages. Infect Immun 1999; 67:885-90.
13. 13. Ren Y, Savill J. Proinflammatory cytokines potentiate thrombospondin-mediated phagocytosis of neutrophils undergoing apoptosis. J Immunol 1995; 154:2366-74.
14. 14. Bowman EJ, Siebers A, Altendorf K. Bafilomycins: a class of inhibitors of membrane ATPases from microorganisms, animal cells, and plant cells. Proc Natl Acad Sci USA 1988; 85:7972-6.
15. 15. Mazzolla R, Barluzzi R, Brozetti A, et al. Enhanced resistance to Cryptococcus neoformans infection induced by chloroquine in a murine model of meningoencephalitis. Antimicrob Agents Chemother 1997; 41:802-7.
16. 16. Wang Y, Casadevall A. Susceptibility of melanized and nonmelanized Cryptococcus neoformans to the melanin-binding compounds trifluoperazine and chloroquine. Antimicrob Agents Chemother 1996; 40:541-5.
17. 17. Odom A, Muir S, Lim E, Toffaletti D, Perfect J, Heitman J. Calcineurin is required for virulence of Cryptococcus neoformans. EMBO J 1997; 16: 2576-89.
18. 18. Nelson H, Nelson N. Disruption of genes encoding subunits of yeast vacuolar H'-ATPase causes conditional lethality. Proc Natl Acad Sci USA 1990; 87:3503-7.
19. 19. Rothman JH, Yamashiro CT, Raymond CK, Kane PM, Stevens TH. Acidification of the lysosome-like vacuole and the vacuolar H+-ATPase are deficient in two yeast mutants that fail to sort vacuolar proteins. J Cell Biol 1989; 109:93-100.
20. 20. Mason DL, Wilson CL. Cytochemical and biochemical identification of lysosomes in Cryptococcus neoformans. Mycopathologia 1979; 68:183-90.
21. 21. Dise CA, Burch JW, Goodman DB. Direct interaction of mepacrine with erythrocyte and platelet membrane phospholipid. J Biol Chem 1982; 257: 4701-4.
22. 22. Volpi M, Sha'afi RI, Epstein PM, Andrenyak DM, Feinstein MB. Local anesthetics, mepacrine, and propanolol are antagonists of calmodulin. Proc Natl Acad Sci USA 1981; 78:795-9.
23. 23. Mustonen P, Lehtonen JY, Kinnunen PK. Binding of quinacrine to acidic phospholipids and pancreatic phospholipase A2: effects on the catalytic site of the enzyme. Biochemistry 1998; 37:12051-7.
24. 24. Sorensen M, Sehested M, Jensen PB. pH-dependent regulation of camptothecin-induced cytotoxicity and cleavable complex formation by the antimalarial agent chloroquine. Biochem Pharmacol 1997; 54:373-80.
25. 25. Jacoby EM, Schlichting I, Lantwin CB, Kabsch W, Krauth-Siegel RL. Crystal structure of the Trypanosoma cruzi trypanothione reductase/mepacrine complex. Proteins 1996; 24:73-80.
26. 26. Barr R, Branstetter BA, Rajnicek A, Crane FL, Low H. Chloroquine-sensitive transplasmalemma electron transport in Tetrahymena pyriformis: a hypothesis for control of parasite protozoa through transmembrane redox. Biochim Biophys Acta 1991; 1058:261-2.
27. 27. Manhart A, Kalisz H, Holzer H. Sensitivity of yeast glycolytic enzymes to chloroquine. Arch Microbiol 1988; 150:309-12.
28. 28. Byrd TF, Horwitz MA. Chloroquine inhibits the intracellular multiplication of Legionella pneumophila by limiting the availability of iron. A potential new mechanism for the therapeutic effect of chloroquine against intracellular pathogens. J Clin Invest 1991; 88:351-7.
29. 29. Newman SL, Gootee L, Brunner G, Deepe GS Jr. Chloroquine induces human macrophage killing of Histoplasma capsulatum by limiting the availability of intracellular iron and is therapeutic in a murine model of histoplasmosis. J Clin Invest 1994; 93:1422-9.
30. 30. Diem K, Lentner C. Documenta Geigy scientific tables. 7th ed. Basel, Switzerland: J. R. Geigy, 1970.
31. 31. French JK, Hurst NP, O'Donnell ML, Betts WH. Uptake of chloroquine and hydroxychloroquine by human blood leukocytes in vitro: relation to cellular concentrations during antirheumatic therapy. Ann Rheum Dis 1987; 46:42-5.
32. 32. Lee SC, Dickson DW, Casadevall A. Pathology of cryptococcal meningo-encephalitis: analysis of 27 patients with pathogenetic implications. Hum Pathol 1996; 27: 839-47.
33. 33. Kligman AM, Weidman FD. Experimental studies on treatment of human torulosis. Arch Dermatol Syph 1949; 60:726-41.
34. 34. Stone JW, Wise R. Penetration of antimicrobial agents into the central nervous system. In: Lambert HP, ed. Infections of the central nervous system. Philadelphia: B. C. Decker, 1991:40-74.
35. 35. McChesney EW, Banks WF, Fabian RJ. Tissue distribution of chloroquine, hydroxychloroquine, and desethylchloroquine in the rat. Toxicol Appl Pharmacol 1967; 10:501-13.
36. 36. McChesney EW. Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate. Am J Med 1983; 75:11-8.
37. 37. Oldham FK, Kelsey FE. Studies on antimalarial drugs: the distribution of atabrine in the tissues of the fowl and the rabbit. J Pharmacol Exp Ther 1945; 83:288-93.
38. 38. Dearborn EH, Kelsey FE, Oldham FK, Geiling EMK. Studies on antimalarials: the accumulation and excretion of atabrine. J Pharmacol Exp Ther 1943; 78:120-6.